-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $14

Benzinga·07/30/2026 19:15:31
Listen to the news
Needham analyst Ami Fadia maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and lowers the price target from $15 to $14.